Alpha-Ketoglutarate (AKG) for Aging: What the Research Actually Shows
TL;DR: Alpha-ketoglutarate (AKG) is a metabolite in the Krebs cycle that declines by roughly 50% between ages 40 and 70. A 2020 Cell Metabolism study found calcium AKG extended median lifespan in mice by up to 12% and compressed the period of decline at end of life. A 2021 human study in 42 adults reported an average 8-year reduction in biological age after 7 months of AKG supplementation. That human study had no control group, was industry-funded, and used epigenetic clock scores rather than health outcomes. The first proper randomized controlled trial (ABLE, n=120) is currently running. AKG is worth watching closely, but the human evidence is not yet robust enough to call it proven.
Table of Contents
- The Short Answer: What Does the Research Show?
- What Is AKG and Why Does It Matter for Aging?
- Key Studies Explained
- What the Evidence Actually Supports (and What It Doesn’t)
- Practical Takeaways: Dose, Form, What to Look For
- FAQ
- Conclusion
- References
The Short Answer: What Does the Research Show?
| Study | Design | n | Key Finding | Evidence Quality |
|---|---|---|---|---|
| Shahmirzadi et al. 2020 (PMID 32877690) | Controlled animal trial | Hundreds of mice | Median lifespan extended up to 12% (female); morbidity compressed | Strong for mechanism and animal lifespan |
| Demidenko et al. 2021 (PMC 8660611) | Retrospective, uncontrolled human study | 42 adults | Avg 8-year reduction in biological age (TruAge clock) after avg 7 months | Weak: no control group, industry-funded |
| Su et al. 2019 (PMC 6629006) | Animal trial (Drosophila) | Multiple cohorts | Lifespan extended via mTOR inhibition and AMPK activation | Moderate: mechanistic, invertebrate only |
| ABLE Trial 2025 (PMID 40819772) | RCT ongoing | 120 adults aged 40-60 | Biological age as primary endpoint: results pending | Pending: first proper human RCT |
What Is AKG and Why Does It Matter for Aging?
Alpha-ketoglutarate is not a supplement in the traditional sense. It is an endogenous metabolite — a compound your body produces continuously as part of the citric acid cycle (also called the Krebs or TCA cycle), which drives energy production in every cell. AKG sits at a metabolic crossroads: it participates in amino acid synthesis, collagen production, and oxidative phosphorylation, and it serves as a required cofactor for a class of enzymes called alpha-ketoglutarate-dependent dioxygenases — which include the enzymes responsible for DNA and histone demethylation.
That last function is why aging researchers became interested in it. Epigenetic changes — shifts in which genes are silenced or expressed, driven partly by methylation patterns — are a central hallmark of aging. AKG-dependent dioxygenases are required to reverse some of these changes. When AKG levels fall, this class of enzymes becomes substrate-limited, potentially allowing epigenetic drift to accelerate.
Blood AKG levels decline substantially with age. Animal data and indirect human measurements suggest a roughly 50% reduction between early adulthood and age 60 to 70. This is not a disease state — it is a normal consequence of reduced mitochondrial activity and TCA cycle flux. But it raises a specific question: can restoring AKG through supplementation slow the epigenetic and metabolic consequences of that decline?
Key Studies Explained
Study 1: Cell Metabolism 2020 — Lifespan Extension in Mice
The most cited AKG study was published in Cell Metabolism in September 2020 (PMID 32877690). Researchers at the Buck Institute for Research on Aging fed calcium AKG (CaAKG) to middle-aged mice starting at 18 months, roughly equivalent to 55 to 60 human years. Female mice treated with CaAKG showed a median lifespan increase of approximately 12%. Male mice showed roughly 6%. The treatment also compressed morbidity: mice spent a smaller fraction of their lives in physical decline. They did not simply live longer in poor condition. Healthy function was extended proportionally more than total lifespan.
The mechanisms: AKG suppresses ATP synthase activity (mimicking some caloric restriction effects), inhibits mTOR signaling, activates AMPK, reduces systemic inflammatory cytokines including TNF-alpha and IL-6, and modulates the epigenetic landscape through its role as a dioxygenase cofactor. Multiple independently documented aging pathways converge on a single compound.
Study 2: Aging 2021 — Human Epigenetic Clock Data
The only published human data comes from a 2021 study in the journal Aging (PMC 8660611). Forty-two adults took Rejuvant — a formulation combining calcium AKG with B vitamins — for an average of 7 months. Their biological age was measured using the TruAge DNA methylation clock at baseline and after supplementation.
The result: an average reduction in biological age of 8 years across the cohort (p-value 6.5 × 10⁻¹²). That p-value looks striking, but the study design limits what can be concluded. There was no placebo control group. Without a control, the clock reduction could reflect the supplement, lifestyle changes, regression to the mean in initial scores, or any combination. The study was also funded by TruMe, the company that sells Rejuvant. An 8-year epigenetic age reduction after 7 months of supplementation, if real and replicable in a controlled trial, would be among the most significant longevity findings in human research. That is exactly why the ABLE trial matters.
Study 3: Drosophila 2019 — Mechanism via mTOR and AMPK
A 2019 study in Aging (PMC 6629006) found that AKG supplementation extended lifespan in fruit flies via inhibition of TOR and activation of AMPK — the same pathways implicated in caloric restriction’s lifespan benefits across species. The fly data adds mechanistic confidence to the mouse findings and suggests the AKG-longevity connection is not mammal-specific.
Study 4: ABLE Trial 2025 — The First Human RCT
The ABLE trial (NCT05706389) is a double-blind, randomized, placebo-controlled trial enrolling 120 adults aged 40 to 60 whose biological age exceeds their chronological age by DNA methylation clock. A 2025 paper (PMID 40819772) described the trial’s recruitment evaluation and design. Results are expected in late 2025 or 2026. This is the study that will determine whether the Rejuvant finding holds under controlled conditions.
What the Evidence Actually Supports (and What It Doesn’t)
What the evidence supports: AKG extends lifespan in two independent animal models through documented mechanisms that overlap with established longevity pathways. A human supplementation study showed a large epigenetic clock reduction consistent with the animal data direction.
What the evidence does not support: No controlled human trial has confirmed that AKG reduces biological age. Epigenetic clock scores do not directly measure health outcomes. And not all AKG supplements are equivalent — the longevity research used calcium AKG (CaAKG). Arginine AKG (AAKG), which dominates sports supplement shelves, is a different compound used for vasodilation and was not studied for aging. Using AAKG and expecting longevity effects is a category error.
Practical Takeaways: Dose, Form, What to Look For
Form matters most. Confirm your supplement uses calcium AKG (CaAKG), not arginine AKG. Check the label.
Dose. The Rejuvant formulation provided approximately 1,000mg of AKG per day alongside B vitamins. Mouse studies used a dietary dose that scales to roughly 1,000 to 2,000mg/day in human terms. No established optimal human dose exists yet — 1,000mg/day is the best current approximation.
Safety. AKG is an endogenous metabolite. No significant adverse effects have been reported at supplemental doses in the studied range. It is available OTC without a prescription.
For CaAKG, Double Wood Supplements Alpha Ketoglutaric Acid provides 1,000mg calcium AKG per serving — the form and approximate dose used in the research. (Disclosure: affiliate link. I earn a small commission at no additional cost to you.)
For a formulation closer to the Rejuvant protocol (AKG combined with B-vitamin cofactors), Life Extension Alpha-Ketoglutarate with Vitamins pairs CaAKG with the B vitamins used alongside AKG in the human study. (Disclosure: affiliate link. I earn a small commission at no additional cost to you.)
Frequently Asked Questions
What does AKG do in the body?
AKG is a core intermediate in the citric acid cycle driving cellular energy production. It also serves as a cofactor for enzymes that regulate epigenetic modifications, participates in amino acid synthesis, and modulates mTOR and AMPK signaling — pathways central to cellular aging.
Does AKG decline with age?
Yes. Blood and tissue AKG levels decline by an estimated 50% between early adulthood and the seventh decade, associated with reduced TCA cycle activity and mitochondrial function — both established hallmarks of cellular aging.
What did the mouse study actually find?
The 2020 Cell Metabolism study (PMID 32877690) found CaAKG extended median lifespan by roughly 12% in female mice and 6% in males when started in middle age. It also compressed morbidity — the animals spent proportionally less of their lives in decline. Frailty scores improved and inflammatory markers decreased.
Is the 8-year biological age reduction real?
The measurement is real. Whether it reflects genuine biological rejuvenation, a statistical artifact of the uncontrolled design, or lifestyle confounds is unknown until the ABLE RCT confirms or refutes it. The effect size is large enough that if it holds up in a controlled trial, it would be a landmark finding.
What is the difference between CaAKG and AAKG?
Calcium AKG (CaAKG) is AKG bound to calcium — the form used in longevity research. Arginine AKG (AAKG) is AKG bound to arginine — common in pre-workout supplements for vasodilation. The aging findings apply to CaAKG specifically. Do not substitute AAKG expecting longevity effects.
Should I take AKG now or wait for trial results?
The safety profile is favorable — AKG is endogenous and well-tolerated. The mechanistic case is strong and the animal data solid. The human longevity evidence is preliminary but directionally consistent. Whether to supplement now or wait for the ABLE results depends on your personal tolerance for acting on incomplete evidence.
How long before AKG might show effects?
The Rejuvant human study used an average of 7 months before measuring epigenetic clock changes. No data exists on how quickly clinical outcomes might change. Seven months is the best current estimate for when epigenetic markers might shift.
Conclusion: Strong Mechanisms, Early Human Data, One Trial Pending
AKG occupies a specific position in the longevity supplement landscape. It is not a novel molecule — it is something your body already makes and depends on, and its levels measurably decline with age. The animal data showing lifespan extension is methodologically credible. The mechanisms are documented and overlap with pathways known to matter for aging across multiple species.
The human data is the weak point. A single uncontrolled study showing an 8-year epigenetic age reduction is intriguing but not confirmatory. The ABLE trial, when its results are published, will be the first real test of whether AKG changes biological age under controlled conditions in humans. Until then, AKG belongs in the category of well-mechanized, animal-validated, human-unconfirmed longevity interventions. That is not a dismissal. It is where the evidence currently stands.
Continue reading:
- Spermidine and Immune Aging: The Protocol a 2026 Trial Actually Tested
- NAD+ and NMN Supplementation: What the Aging Evidence Shows
- Senolytics: What the Human Trial Data Actually Shows
References
- Shahmirzadi AA et al. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. Cell Metab. 2020;32(3):447-456. PMID: 32877690
- Demidenko O et al. Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging. Aging. 2021;13(22):24485-24499. PMC: 8660611
- Su Y et al. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK. Aging. 2019;11(12):4183-4197. PMC: 6629006
- Chin RM et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014;510(7505):397-401. PMID: 24828042
- He W et al. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nat Commun. 2020;11(1):5596. PMID: 33154393
- ABLE trial recruitment evaluation: PMID 40819772
